(Q57591345)

English

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

scientific article published on 17 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

type 2 diabetes

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Hirotaka Watada

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maximilian von Eynatten

9

object named as

M von Eynatten

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

R Kawamori

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

E Araki

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

N Hayashi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Y Horie

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

A Sarashina

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Y Gong

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

H J Woerle

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

K A Dugi

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

17 January 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

348-357

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

GLP-1: physiological effects and potential therapeutic applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Incretin effects on β-cell function, replication, and mass: the human perspective

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Obesity and type 2 diabetes in Japanese patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01545.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01545.X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22145698%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57591345&oldid=1833393991"